Patents Assigned to Merck Patents GmbH
  • Patent number: 9289427
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: March 22, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz-Hermann Bokel, Frank Stieber, Cristina Donini
  • Publication number: 20160077068
    Abstract: The present invention relates to a thin-layer chromatography plate at least consisting of a support and a sorbent layer, where the sorbent layer comprises at least one siloxane oligomer, to a process for the production thereof, and to a method for carrying out a thin-layer chromatographic separation using said thin-layer chromatography plate.
    Type: Application
    Filed: March 17, 2014
    Publication date: March 17, 2016
    Applicant: Merck Patent GmbH
    Inventor: Michael SCHULZ
  • Patent number: 9284300
    Abstract: Compounds of formula (I) and their uses as inhibitors of tyrosine kinases, in particular Met kinase, and their employment in methods for the treatment of tumors.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 15, 2016
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Frank Stieber, Oliver Schadt, Andree Blaukat
  • Patent number: 9287505
    Abstract: The invention relates to novel polymers containing repeating units based on thieno[3,4-b]thiophene, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: March 15, 2016
    Assignee: Merck Patent GmbH
    Inventors: Nicolas Blouin, William Mitchell, Miguel Carrasco-Orozco, Frank Egon Meyer, Steven Tierney
  • Patent number: 9283225
    Abstract: Compounds of the formula I in which Het, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of RON and can be employed, for the treatment of cancer.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: March 15, 2016
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Oliver Schadt, Christine Knuehl, Manja Friese-Hamim, Bayard R. Huck, Andreas Goutopoulos, Nadia Brugger
  • Patent number: 9287504
    Abstract: The invention relates to novel polymers containing repeating units based on benzodifuran, benzodipyrrole or benzodithiophene, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: March 15, 2016
    Assignee: Merck Patent GmbH
    Inventors: Nicolas Blouin, Steven Tierney, William Mitchell, Miguel Carrasco-Orozco, Frank Egon Meyer
  • Patent number: 9287052
    Abstract: The present invention relates to the use of at least one tertiary amine-N-oxide of formula I as additive in dye-sensitized solar cells and to special electrolyte formulations and a dye-sensitized solar cell comprising at least one compound of formula I.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 15, 2016
    Assignee: Merck Patent GmbH
    Inventors: Hiroki Yoshizaki, Kentaro Kawata, Tomohisa Goto, Hiromi Shinohara, Peter Kirsch
  • Publication number: 20160067322
    Abstract: The invention is directed to the treatment of lung cancer, preferably non-small cell lung cancer (NSCLC) by means of a combination therapy comprising concurrent chemo-radiotherapy followed by vaccination with a muc-1 lipopetide. The therapy elicits prolonged survival rates compared to a respective therapy including sequential chemo-radiotherapy.
    Type: Application
    Filed: April 14, 2014
    Publication date: March 10, 2016
    Applicant: MERCK PATENT GmbH
    Inventors: Andreas SCHROEDER, Christoph HELWIG, Anja-Helena LOOS, Armin SCHUELER, Martin FALK, Charles BUTTS, Frances A. SHEPHERD
  • Publication number: 20160068755
    Abstract: The invention relates to a layer or article comprising cholesteric liquid crystal polymer particles, which are optionally dispersed in a continuous phase, to cholesteric polymer particles for use in such a layer or article, to methods of preparing such a layer or article, and to the use of such a layer or article as optical element, in windows or electrooptical devices like liquid crystal displays (LCDs).
    Type: Application
    Filed: March 19, 2014
    Publication date: March 10, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Eduardo BELTRAN GRACIA, Owain Llyr PARRI
  • Patent number: 9279082
    Abstract: Polymerizable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (“polymer sustained”) or PSA (“polymer sustained alignment”) type.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: March 8, 2016
    Assignee: Merck Patent GmbH
    Inventors: Andreas Taugerbeck, Achim Goetz, Alexander Hahn, Martin Engel
  • Publication number: 20160060528
    Abstract: The invention relates to compounds of the formula I, in which X1, X2, Sp, and R are as defined herein, and to the use thereof in liquid-crystal media, but also to the use of these liquid-crystal media in liquid-crystal displays, and also to liquid-crystal displays of this type per se.
    Type: Application
    Filed: August 31, 2015
    Publication date: March 3, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Achim GOETZ, Rocco FORTTE, Martin ENGEL, Sabrina MAAG, Ingo ALMEROTH, Thomas MERGNER, Thorsten KODEK, Detlef PAULUTH
  • Publication number: 20160060530
    Abstract: The present invention relates to a temperature-reactive device for the regulation of light transmission, containing a liquid-crystalline medium and a compound of formula I, capable of promoting or inducing homeotropic alignment to the adjacent liquid crystal medium at a given temperature. The invention furthermore relates to a process for the temperature-dependent control of light transmission through a layer of a liquid-crystalline medium.
    Type: Application
    Filed: March 28, 2014
    Publication date: March 3, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Graziano ARCHETTI, Andreas TAUGERBECK
  • Patent number: 9273029
    Abstract: Compounds of the formula (I) in which R, R1 and X have the meanings indicated in claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: March 1, 2016
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Hans-Michael Eggenweiler, Srinivasa R. Karra
  • Publication number: 20160053170
    Abstract: The invention relates to co-activated magnesium alumosilicate based phosphors, to a process of its preparation, the use of these phosphors in electronic and electro optical devices, such as light emitting diodes (LEDs) and solar cells and especially to illumination units comprising said magnesium alumosilicate-based phosphors.
    Type: Application
    Filed: February 24, 2014
    Publication date: February 25, 2016
    Applicant: Merck Patent GmbH
    Inventors: Hiroshi OKURA, Takeo WAKIMOTO, Katsuyuki MATSUI, Noriyuki MATSUDA
  • Publication number: 20160053175
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising a polymerisable compound, one or more compounds of formula Q, and one or more compounds of formula AN1 to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display, comprising it.
    Type: Application
    Filed: August 17, 2015
    Publication date: February 25, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Dong-Mee SONG, Eun-Kyu LEE, Seung-Eun LEE
  • Publication number: 20160054602
    Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerizable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
    Type: Application
    Filed: August 24, 2015
    Publication date: February 25, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Qiong TONG, Nico SCHWEBEL, Eveline BARON, Christoph MARTEN
  • Publication number: 20160053178
    Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, wherein the radicals R11, L1, L2, n and A are as defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PA-VA, PALC, FFS, PS-FFS, IPS or PS-IPS effect.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 25, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Harald HIRSCHMANN, Martina WINDHORST, Monika BAUER, Volker REIFFENRATH, Matthias BREMER
  • Patent number: 9267078
    Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy (??), which is distinguished by the fact that it has a value for the ratio ?1/?n2 in the range 6-45 with a clearing point of >60° C. and a ?? of ??2.3. Media of this type are particularly suitable for electro-optical displays having active-matrix addressing based on the ECB, PA LCD, FFS or IPS effect.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 23, 2016
    Assignee: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Sabine Schoen
  • Patent number: 9266887
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: February 23, 2016
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
  • Publication number: 20160046863
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds which contains at least one compound of the formula I, and at least one additional compound, and to the use of the LC mixtures for an active- or passive matrix addressed displays, in particular based on the VA, PSA, PS-VA, IPS, FFS, PS-IPS, PS-FFS technology, preferably in optical displays for the self-aligning VA mode.
    Type: Application
    Filed: August 14, 2015
    Publication date: February 18, 2016
    Applicant: Merck Patent GmbH
    Inventors: Graziano ARCHETTI, Melanie KLASEN-MEMMER, Rocco FORTTE, Sabine SCHOEN